eClinical Tech News

Corvus Pharmaceuticals reported positive cohort 4 results from its randomized, blinded phase 1 trial of soquelitinib in moderate-to-severe atopic...

ProQR Therapeutics reported year-end 2025 results and a business update centered on advancing its Axiomer RNA editing platform. The...

Gyre Therapeutics is buying Cullgen in an all‑stock deal valued at approximately $300 million, aiming to close in the...

Codexis reported fourth-quarter 2025 revenue of $38.9 million and full-year revenue of $70.4 million, buoyed by a $37.8 million...

Tenaya Therapeutics outlined a 2026 cadence aimed at moving two cardiac gene therapies toward pivotal-readiness while extending its cash...

Pliant Therapeutics has initiated a Phase 1b indication expansion trial for PLN-101095, an oral dual inhibitor of αvβ8 and...

Evaxion has delivered a 2025 reset built on external validation and extended runway. The techbio vaccine developer reported full-year...

Aquestive Therapeutics will resubmit the U.S. NDA for Anaphylm, its sublingual epinephrine film for severe allergic reactions, in the...

ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy, its FDA- and EC-approved intranasal epinephrine, in...

Enzon Pharmaceuticals has extended the deadline for its exchange offer to convert Series C non-convertible redeemable preferred stock into...